INTRODUCTION
D URING DEVELOPMENT, NEW BLOOD VESSELS originate either from endothelial cell precursors (angioblasts) by a process called vasculogenesis or from preexisting blood vessels by angiogenesis. Both processes are tightly regulated by direct interaction of the endothelial cells or endothelial cell precursors, with agents bound to the extracellular matrix of adjacent cells, and by various chemoattracting stimuli, including paracrine and autocrine growth factors. 1 These soluble and bound chemoattractants may cooperate, and often multiple factors are required. Substantial information about the molecular and cellular biology of vasculogenesis and angiogenesis has been obtained by in vitro studies employing endothelial cells, isolated from either capillaries or large blood vessels. [2] [3] [4] The most crucial elements in the vasculogenic and angiogenic cascades, which include cell proliferation, apoptosis, differentiation, and migration, can be assessed in vitro.
Cell proliferation can be measured by direct counting of viable cells, thymidine incorporation, immunohistochemical staining for cell proliferation, or metabolism of certain compounds. Cell apoptosis can be measured in a variety of ways, including terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (the Tunel assay 5 ) or monitoring of nuclear fragmentation. Cell differentiation and migration can be induced in vitro by culturing endothelial cells and endothelial cell precursors in the presence of different components of the extracellular matrix. 6 Cell migration has 2 major components: directional migration and random migration. Random migration occurs when the cells migrate independently of a gradient of a chemotactic stimulus of paracrine or autocrine nature. Directional migration, or chemotaxis, is exhibited when cells detect, recognize, and move along the chemoattractant gradient. [6] [7] [8] [9] Cell migration has been examined by a wound-healing assay 3 and by a quantitative method developed by Boyden. 10 Currently, the term Boyden chamber is widely applied to any chemotaxis chamber, and most modern chemotaxis assays are variants or extensions of Boyden's original assay. In the Boyden assay, 2 chambers are separated by a microporous membrane. A cell suspension is loaded into 1 chamber, and medium supplemented with the chemoattractant (e.g., vascular endothelial growth factor [VEGF] or fetal bovine serum [FBS] ) is placed into the other chamber, forming a very steep gradient. The cells migrate toward the chemoattractant through the membrane, and the migrated cells are quantified. The Boyden assay is easy to use, can measure random and directional migration, and can be used to screen multiple compounds under different conditions. This assay is limited, however, as only 1 chemotactic gradient can be established, the gradient is steep, there is no control over the rate of cell migration, and monitoring cell migration in real time is still technically complicated. The migrated cells can be quantified by count-ing the fixed and stained cells on the bottom side of the microporous membrane; by labeling with a fluorescent dye, before or after migration, and measuring the fluorescent signal from the migrated cells; or by enzymatic assays such as myeloperoxidase.
BD Biosciences has developed a modified Boyden assay, the BD BioCoat ™ Angiogenesis System, composed of a BD FluoroBlok ™ insert plate, containing a polyethylene terephthalate (PET) fluorescence-blocking microporous membrane (22 ± 3 µm in thickness with 3.0 ± 0.3-µm pores) evenly coated with human fibronectin, which allows endothelial cells to attach and migrate. The viable migrated cells are labeled with Calcein AM 11, 12 and their fluorescence measured. Nonmigrated cells are not detected, as their fluorescence is blocked by the opaque PET membrane.
The BD assay has been improved, as described in this article, by developing an automated microscope-based endothelial cell migration assay (automated cell migration [ACM]). In this assay, using 24-or 96-well versions of BD FluoroBlok ™ inserts, migrated endothelial cells are fixed, and the cell nuclei, after staining with the fluorescent dye Hoechst 33342, are counted with an automated microscope (Cellomics HCS ArrayScan 3.1), using a modified software protocol from Cellomics, Inc.
In this study, ACM was directly compared to Calcein AM staining and shown to be superior in terms of signal to background. ACM was further characterized by studying the time course of migration, VEGF concentration dependence, and concentrationdependent inhibition of VEGF-induced migration. [13] [14] [15] [16] [17] [18] [19] The migration of at least 2 primary endothelial cell lines-human umbilical vein endothelial cells (HUVECs) isolated from large blood vessels and human microvascular endothelial cells (HMVECs) isolated from adult dermis microvessels-was successfully measured with ACM.
The quantitative migration assay system described here provides a powerful tool for fast, reliable characterization and quantitation of endothelial cell migration, which can be used to screen for angiogenic or angiostatic compounds. In addition, ACM can be easily applied to a cell invasion assay in which the fluorescence-blocking PET microporous membrane coated with matrigel is used.
MATERIALS AND METHODS

Compounds
A phthalazine compound PTK787 (also known as PTK787/ ZK222584) [13] [14] [15] [16] [17] [18] and anthranilamide compound 5 (AAL993) 19 were synthesized in the Department of Oncology (Novartis Pharmaceuticals Corporation). The characterization of PTK787/ ZK222584 is a joint development project between Novartis Pharma AG (Basel, Switzerland) and Schering AG (Berlin, Germany). Stock solutions of PTK787 and AAL993 were prepared in DMSO and were diluted further with cell culture medium so that the final concentration of DMSO did not exceed 0.5% (v/v).
Cells
HUVECs (lot number NCI-02), pooled from multiple donors, were obtained from Vec Technologies (Rensselaer, NY). HMVECs, isolated from a single donor, were obtained from Cascade Biologics (Portland, OR). The cells were grown in VEGFcontaining EGM-2 MV complete media (Cambrex Corporation, East Rutherford, NJ) until 50% to 70% confluent in T75 Flasks (Corning Incorporated, Corning, NY, cat. 430641).
Endothelial cell migration was measured in the BD BioCoat ™ Angiogenesis System (BD Biosciences, Bedford, MA) using BD Falcon FluoroBlok ™ 24-well (cat. 354143) or 96-well (custommade) insert plates. Cell monolayers of a low passage number (below 5) were washed once with HEPES-buffered saline solution (Cambrex Corporation), mildly trypsinized, and resuspended in EBM-2 serum-free cell culture medium (Cambrex Corporation) containing 0.1% delipidized bovine serum albumin (BSA; BD Biosciences). For testing inhibitors, cell suspensions were preincubated with each compound for 30 min at 37°C in a CO 2 incubator prior to cell migration assays. The bottom chambers of a FluoroBlok ™ were filled with 0.75 mL (24-well insert) or 0.2 mL (96-well insert) of EBM-2 medium containing 0.1% delipidized BSA supplemented as appropriate with 1 to 50 ng/mL VEGF (R& D Systems, Minneapolis, MN) or 5% FBS (Cambrex Corporation). The FluoroBlok ™ inserts were placed into the wells, and cell suspension was added to each top chamber in a final volume of 0.25 mL for a 24-well insert (50,000 or 100,000 cells) or 0.05 mL for a 96-well insert (15,000 cells). The cells were allowed to migrate for 2 to 24 h at 37°C in a CO 2 incubator. All treatments were done in triplicate for the 24-well insert or in quadruplicate for the 96-well inserts.
Cell labeling with Calcein AM
Labeling with Calcein AM (Molecular Probes, Eugene, OR) was performed as described by Maliakal. 12 Briefly, following the migration assay, each FluoroBlok ™ insert was transferred into a nontissue culture 24-well plate (BD Biosciences) containing 0.5 mL/well Calcein AM solution (4 µg/mL in Hanks balanced salt solution [HBSS], Invitrogen, Carlsbad, CA), incubated for 1.5 h at 37°C in a CO 2 incubator, and then transferred into another nontissue culture 24-well plate containing 0.5 mL of HBSS. The migrated cells were quantified by measuring the fluorescent signal derived from the underside of the membrane using a CytoFluor4000 fluorescence plate reader (excitation = 485 nm, emission = 530 nm, gain = 55).
Cell nuclei imaging
Following cell migration, the cells were fixed by transferring the FluoroBlok ™ insert into a 24-or 96-well plate containing 0.8 or 0.2 mL, respectively, of 3.7% formaldehyde in PBS (154 mM NaCl, 1.54 mM KH 2 PO 4 , 2.86 mM Na 2 HPO 4 , pH 7.2) per well at Quantitative High-Throughput Endothelial Cell Migration Assay room temperature for 10 min. Fixed cells were washed 3 times for 1 min at room temperature in PBS. During the first wash, the cell suspension was completely aspirated from the top chambers of the FluoroBlok ™ insert. The cells were stained in 1 or 0.2 mL per well, respectively, of 5 µg/mL Hoechst 33342 (Molecular Probes) in PBS at room temperature for 10 min, then washed 3 times in PBS. Stained cell nuclei were counted on the underside of the FluoroBlok ™ insert by an automated microscope contained in the Cellomics HCS ArrayScan 3.1 (Cellomics, Pittsburgh, PA) and analyzed using the Cellomics ArrayScan ® receptor internalization protocol. This program was modified by adjusting the x, y, and z offsets for 24-or 96-well plates; selecting the number of fields to be scanned per well; and setting the software to output the number of nuclei that it counts. The 5× (6 predetermined fields per well) and the 10× (25 predetermined fields per well) objectives were used for the 24-well insert, and the 10× objective (9 predetermined fields per well) was used for 96-well inserts.
RESULTS AND DISCUSSION
Comparison of Calcein AM labeling and ACM
The 24-well BD FluoroBlok ™ insert contains 24 individual Boyden chambers equipped with the fluorescence-blocking PET microporous (3.0 ± 0.3-µm pore size) membrane evenly coated with human fibronectin. Cell migration was measured by 2 methods: (1) by measuring total fluorescence after Calcein AM labeling of viable cells, a standard method for quantifying cell migration, or (2) by direct counting of the cells after staining nuclei, as described in Materials and Methods. To compare Calcein AM labeling and cell nuclei counting, the signal obtained with a chemoattractant is expressed as a ratio of the signal in the absence of a chemoattractant, where only random migration occurs. Using ACM, the rate of VEGF-induced directional migration was 20 to 35 times greater than the control compared to a 2-to 3-fold increase detected in a parallel experiment using Calcein AM labeling. As expected, FBS was a more powerful chemoattractant than VEGF, resulting in a 140-to 250-times increase in cell migration detected with ACM compared to only a 12-fold increase using Calcein AM labeling ( Fig. 1 ). Hence, ACM has a more than 10fold higher signal to background than Calcein AM labeling.
This increase in signal to background of ACM over Calcein AM labeling may be due to a variety of reasons. The passage of the endothelial cell through the 3.0-µm pore imposes stress on the cell, which may affect its metabolism and viability. Because nonfluorescent Calcein AM, a cell-permeant compound, must be converted to green-fluorescent Calcein by intracellular esterases in viable cells, metabolically compromised or dead migrated cells will not produce detectable green-fluorescent Calcein. On the other hand, cell nuclei staining with Hoechst 33342 does not depend on either cell viability or metabolic state. In addition, nonmigrated cells can be seen to be stuck within the pores of the membranes. It is likely that these nonmigrated cells may also con-tribute to a higher background signal in the Calcein AM procedure, further reducing its signal-to-background ratio.
Interestingly, the addition of FBS only to the top chamber produced the same effect on cell migration as observed for FBS added to the bottom chamber or both chambers simultaneously (data not shown). This observation indicates that FBS induces such strong random migration of the endothelial cells that the directional component, if any, cannot be detected in this assay. However, due to its strong effect on endothelial cell migration, FBS is a useful positive control. ACM showed significantly higher signal-to-background than when measuring total fluorescence using Calcein AM, which allowed a more accurate measurement of VEGF-induced migration.
Time course of migration and VEGF concentration dependence
To further characterize the migration of HUVECs, we determined the time course of migration toward VEGF and FBS using 50,000 and 100,000 cells per well. Measurable migration occurred within 1 h (Fig. 2) , and the number of migrated cells progressively increased over 24 h. Although more cells migrated toward VEGF . Cell culture and the endothelial cell migration assay were performed as described in Materials and Methods. A total of 50,000 cells transferred into replicate wells of 24-well BD FluoroBlok ™ plates were allowed to migrate toward 10 ng/mL vascular endothelial growth factor (VEGF), 5% fetal bovine serum (FBS), or no chemoattractant as a control. After 8 h, triplicate treatment wells were stained with Calcein AM, and the total fluorescence was determined for each well. Triplicate treatment wells were also stained with Hoechst 33342 and the nuclei visualized and counted with Cellomics HCS ArrayScan 3.1, using either a 5× or 10× objective. The signal with each chemoattractant was expressed as a ratio of the signal obtained with no chemoattractant for each measurement method. and FBS with 100,000 cells per well, random migration was also higher. As a result, the signal relative to the control for 100,000 cells was lower than for 50,000 cells ( Table 1 ). Because VEGFinduced migration in the plates appeared maximal at 50,000 cells per well for 8 h, these conditions were used in most subsequent experiments.
VEGF, a multifunctional cytokine that is required for angiogenesis occurring under normal and pathophysiological conditions, stimulates endothelial cell proliferation and migration and increases vascular permeability. [20] [21] [22] [23] VEGF induced HUVECs to migrate in a concentration-dependent manner, with a maximum at 10 ng/mL for the 24-well format and 5 ng/mL for the 96-well format (Fig. 3) , which is similar to published values. 12 This difference in optimal VEGF concentration, which we have reproducibly observed, may be due to differences in cell density and/or well geometry, as it is known that cell-cell contacts are very important for HUVEC migration.
Migration of other endothelial cells
Endothelial cells form the inner surface layer of blood and lymphatic vessels. Given the variety of blood and lymphatic vessels and associated differences in localization, structure, nutrient exchange, hemodynamics, and developmental origin, endothelial cells from different vascular beds have local specializations in function and morphology. Thus, any assay of endothelial function should be amenable to studying endothelial cells from different sources. As an initial test, 2 primary endothelial cell lines-HUVECs (cells from a large blood vessel) and HMVECs (cells from small blood vessels)-were compared in ACM. The migration of HMVECs showed similar responses to VEGF-and FBSinduced migration as HUVECs (Fig. 4) .
Inhibition of cell migration by small molecules
The prediction that a specific blockade of endothelial migration would have significant clinical benefit in cancer treatment has prompted the wide search for antiangiogenic compounds. The angiogenic and vasculogenic potential of the VEGF family of proteins is mediated by 2 high-affinity receptors-VEGFR-1 (FLT-1) and VEGFR-2 (KDR), which are located on the surface of the endothelial cells 24, 25 -and a third type of VEGF receptor, VEGFR-3 (also known as FLT4), is expressed in the lymphatic endothelium of adult tissues and also mediates lymphangiogenesis. 26, 27 Therefore, modulation of VEGF-induced cell migration through block- The number of migrated cells (see Fig. 2 ) with each chemoattractant was expressed as a multiple of the number of cells that migrated in the control. VEGF, vascular endothelial growth factor; FBS, fetal bovine serum. 
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ing of the kinase activity of VEGFR-1 and VEGFR-2 is an attractive approach, and several small molecules are known to interfere with the target VEGF/VEGF-receptor system, including phthalazine compound PTK787, also known as PTK787/ ZK222584, [13] [14] [15] [16] [17] [18] and AAL993 (anthranilamide compound 5). 19 These compounds, which have also been shown to inhibit VEGFinduced angiogenesis both in vitro and in vivo, were used to determine if ACM could be used for drug discovery and small-molecule screening.
Using ACM, PTK787 and AAL993 showed concentrationdependent inhibition of VEGF-induced migration of HUVECs, whereas FBS-induced migration was not strongly affected by either of these compounds (Fig. 5 ). The EC 50 was estimated as approximately 50 nM for PTK787 and approximately 25 nM for AAL993 in this assay; these estimates are in line with published results, which, depending on the study, varied from 16 to 100 nM for PTK787 and 1.2 to 130 nM for AAL993. [13] [14] [15] [16] [17] [18] [19] Thus, ACM could accurately identify known antimigratory compounds.
ACM in 96-well plates
Recently, BD Biosciences introduced a 96-well version of its cell migration system, which has the same membrane and human fibronectin coating as the 24-well version. As this format will be easier and cheaper to use in a high-throughput mode, the 96-well format assay was compared to the 24-well format assay to measure the inhibition of VEGF-and FBS-induced migration with VEGFR tyrosine kinase inhibitor AAL993. AAL993 inhibited endothelial cell migration in a concentration-dependent manner, and EC 50 was estimated as 25 nM (Fig. 6) , with a pattern similar to one observed for the 24-well BD FluoroBlok ™ plates (Fig. 5B) . The optimal conditions for the 96-well BD FluoroBlok ™ insert plate used 15,000 cells per well for 8 h.
CONCLUSIONS
In this study, we described and characterized ACM, a much improved method for measuring the migration of endothelial cells that combines the Cellomics HCS ArrayScan 3.1 and BD FluoroBlok ™ insert plates. For both chemoattractants (VEGF and FBS), ACM showed a dramatically better signal-to-background ratio and hence more accurate and robust results than Calcein AM labeling. Using the optimal conditions in 24-and 96-well BD FluoroBlok ™ insert plates (50,000 or 15,000 cells per well, respectively) for 8 h, VEGF induces endothelial cells to migrate in a concentration-dependent manner. This migration can be inhibited by the known VEGFR tyrosine kinase inhibitors PTK787 and AAL993. BD FluoroBlok ™ insert plates are manufactured reproducibly; in a direct comparison of 2 different batches of insert plates, the differences between batches were less than the differences between the wells (data not shown). The measured Z′ factor, as defined by Zhang et al., 28 for this assay under these optimal conditions varies between 0.3 and 0.4, which would indicate that this assay, although not excellent, would be usable as a high-through- put assay. Cells stained for ACM can be stored in the dark for several days before scanning, and with the current software and instrumentation, 96-well BD FluoroBlok ™ inserts can be scanned in 65 min using 9 fields per well, which gives a maximum throughput of about 2000 wells a day.
In Boyden chamber experiments, not all the cells cross the membrane. Under optimal conditions for ACM, between 15% and 25% of the cells migrate in 8 h. This may occur for a number of reasons: (1) a subpopulation of cells may not be competent to migrate;
(2) the gradient is only present for a short period as the components are free to diffuse across the membrane, so the migrating cells are composed of those that migrated during a small time window of directional migration plus any nondirectional migration that also occurs; and (3) the cells require cell-to-cell contact to migrate. Further investigation is required to determine which of the above effects are the most important.
ACM is suitable for testing other primary endothelial cell lines, as demonstrated for HMVECs, and could easily be applied to a cell invasion assay, in which a matrigel-coated fluorescence-blocking PET microporous membrane is used. In principle, the migrated cells could also be stained with other fluorescently labeled antibodies, so multiple cellular events could be monitored after migration takes place. ACM allows fast, reliable characterization and quantitation of endothelial cell migration and should be a powerful tool for discovering angiogenic and angiostatic drugs. Inhibition of vascular endothelial growth factor (VEGF)induced migration by AAL993 in the 96-well format. Cell culture and the endothelial cell migration assay were performed as described in Materials and Methods. Cells were resuspended in basal EBM-2 medium supplemented with 0.1% delipidized bovine serum albumin (BSA) with or without AAL993 and incubated for 30 min in a CO 2 incubator at 37°C. Cell suspension (15,000 cells per well) was transferred into 96-well BD FluoroBlok ™ plates and allowed to migrate toward 10 ng/mL VEGF, 5% fetal bovine serum (FBS), or no chemoattractant as a control. After 8 h, quadruplicate wells were stained with Hoechst 33342 and the nuclei visualized and counted with a Cellomics HCS ArrayScan 3.1 using a 10× objective. Data represent the mean of 4 wells ± 1 standard deviation. . Cell culture and the endothelial cell migration assays were performed as described in Materials and Methods. Cells were resuspended in basal EBM-2 medium supplemented with 0.1% delipidized bovine serum albumin (BSA) with or without compound (PTK787 or AAL993) and incubated for 30 min in a CO 2 incubator at 37°C. Cell suspensions were transferred to 24-well BD FluoroBlok ™ plates (50,000 cells per well) and migrated toward 10 ng/mL VEGF, 5% fetal bovine serum (FBS), or no chemoattractant as a control. After 8 h, triplicate treatment wells were stained with Hoechst 33342 and the nuclei visualized and counted with a Cellomics HCS ArrayScan 3.1 using a 10× objective. Data represent the mean of 3 wells ± 1 standard deviation.
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